

# Hemostemix CEO on autologous stem cell therapy and how it works with circulatory issues

In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXD), about Hemostemix's technology that uses patients own blood to treat ischemia in the circulatory system of the body.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas said, "We take blood from patient's arm. We fractionate out their stem cell from that blood." He continued, "Then we culture them and change them from a raw stem cell into an angiogenic cell precursor that is programmed to address ischemia in the circulatory system of the body. It is common in diabetics, in individuals who suffer from heart disease such as angina or ischemic cardiomyopathy, in wound care."

Thomas stated that Hemostemix has treated more than 500 patients using the technology which is now in clinical trials. He added, "The second one we patented is NCP (Neural Cellular Precursor). This is a cell that can be used to treat stroke, diseases that have nerve damage."

To watch the full interview, click here

## **About Hemostemix Inc.**

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated

Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To know more about Hemostemix Inc., [click here](#)

**Disclaimer:** Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

---

## **Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy**

In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXD), about using Hemostemix’s

patented autologous stem cell therapy platform to treat Ischemia and Angina with significant success in more than 500 patients.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas went on to give an introduction about the origin of the company and talked about the strong management team and well known board members. "I have come across some good technologies and put together a team that have succeeded," Thomas commented.

Thomas also provided an update on Hemostemix's ACP-01 Phase 2 Clinical Trials. ACP-01 uses a patient's own cells to restore blood flow to ischemic limbs and has the potential to treat a range of ischemic diseases.

To watch the full interview, click here

### **About Hemostemix Inc.**

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of

patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To know more about Hemostemix Inc., [click here](#)

**Disclaimer:** Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

---

## **Valeo Pharma on a significant upswing with recent Health Canada approvals**

In a new InvestorIntel interview Peter Clausi speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB: VPHIF), about receiving Health Canada's approval for its anti-coagulant Redesca™ and the use of some its products in battling coronavirus.

"We are in the middle of a significant upswing and growth trajectory," Steve told Peter, with Valeo's stock up over 300% in 12 months. Founded in 2003, Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on neurodegenerative diseases, oncology and hospital specialty products.

Steve discusses Health Canada's recent approval of Redesca™ and Redesca Hp™ low molecular weight heparin (LMWH) biosimilars, which belong to a class of anti-coagulant drugs

very much in demand and are now increasingly used as a first line of defense tool in the fight against the symptoms of COVID-19. Steve added that the Canadian LMWH market is in excess of \$200 million annually and the Valeo anticipates being able to capture a significant market share with its growing portfolio of hospital drug products.

As to future growth and valuation, Steve quoted Wayne Gretzky: "It's not where the puck is, it's where the puck is going, and it's the same thing with valuation. You have to look at where we're going to be in a year or two, and that's what is truly exciting."

To watch the full interview, [click here](#).

***Disclaimer:** Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.*

---

## **Diagnos' Andre Larente on the benefits of using AI for the early detection of critical health issues**

"Our (AI) technology works, its in production (CARA). We are fully funded...the markets we are going after are extremely big..." are excerpts that Andre Larente of Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) offered Tracy Weslosky of InvestorIntel in a recent interview.

Tracy starts the interview by identifying the increasing interest from the global market on the Canadian biotech

sector. She asks Andre to identify their competitive advantages for investors seeking to understand this market better. Andre explains “we specialize in using AI to tackle some of the medical imaging issues in the world.”

[Click here](#) to hear the full interview and learn more about how Diagnos offers early detection medical tests for a wide spectrum of critical medical issues that range from diabetes to cardiovascular issues.

#### About Diagnos:

Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

*Disclaimer: Diagnos Inc. is an advertorial member of InvestorIntel Corp.*

---

# Sixth Wave's Dr. Jon Gluckman talks about the election and the 2nd wave of cannabis investment

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Jon Gluckman, President, CEO and Founder of Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: ATURF) about what a Biden presidential win means for an energized and revitalized cannabis sector.

"We're pretty excited," said Dr. Gluckman, "that in addition to the Biden win it was pretty clear that the referendums on the state ballots in the U.S. were extremely positive and forward-looking for the future of cannabis and the significant expansion in the United States which is obviously a huge market."

Asked about what it means, Dr. Gluckman said that Sixth Wave sees it "as a tremendous opportunity for licensed producers to expand their footprints into different spaces and certainly for new equipment requirements which will include Affinity, so we're stoked." Affinity™ is Sixth Wave's cannabinoid purification system.

Discussing the Affinity cannabinoid purification system revenue model, Dr. Gluckman explains that it work on a "total system performance license" basis, where Sixth Wave provides the technology to licensed cannabis producers on a "small profit margin basis", but then partners to provide upgrades and maintenance in exchange for a portion of the producer's revenue stream. As Sixth Wave's Affinity optimization can save a projected 50% of a producer's production costs, this mutually beneficial arrangement can create a substantial

revenue stream for both the producer and Sixth Wave.

Dr. Gluckman explains to Tracy how the application of Sixth Wave's patented Molecular Imprint Polymers (#MIPs) technology creates "consistent and high purity" cannabinoid from a producer's raw material that is essential to creating a commercial product.

Regarding revenue expectations, Dr. Gluckman said that they expect to see revenue through a deal with Green Envy as early as December, and ramping up in the first quarter of 2021. Answering Tracy's question about investors who missed the "first wave" of cannabis investment, he said that "the very interesting thing now is that what we have seen is that the growers are all growing," and that "as new states come on board they are all going to need new licensed producers." And since there are federal restrictions on interstate movement of cannabis, production will have to be local to each state, requiring multiple production facilities

"We're really looking forward to it and scaling up significantly next year," Dr. Gluckman said.

To watch the full interview on YouTube, [click here](#).

More videos: [click here](#) to subscribe to the InvestorIntel Channel

***Disclaimer:** Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp*

---

## **Sixth Wave's Dr Jon Gluckman**

# on the competitive advantages of Molecular Imprint Polymers for the rapid detection of viruses

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Jon Gluckman, President, CEO and Founder of Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: ATURF) about the application of their patented Molecular Imprint Polymers (#MIPs) technology for the detection of the COVID-19 virus, the flu and virus detection in general.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Dr. Gluckman went on to say that their patented #MIPs technology can identify molecules and may be used for detection of viruses in general and more specifically for COVID-19. He added, "We are in the phase 2 of our development for a COVID-19 test that would be completely synthetic test based on our molecular imprinted polymer technology." Sixth Wave was recently awarded funding from the Nova Scotia COVID-19 Response Council for the development of its Accelerated Molecularly Imprinted Polymer (AMIPs™) technology for the rapid detection of viruses such as SARS-CoV-2.

Speaking on the advantages of their synthetic test Dr. Gluckman said that the two test currently used for COVID-19 detection uses biological material which is fragile and uses tremendous infrastructure to support growing of the biological materials. He explained that Sixth Wave's technology uses synthetic polymers to detect viruses at a very low cost and allows for extended shelf life, minimal storage and handling requirements, and less sensitivity to temperature and light degradation.

To watch the complete interview, [click here](#)

## About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of commercial roll out of its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPS™) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for detection and separation of viruses, biogenic amines and other pathogens, for which the Company has products at various stages of development.

To learn more about Sixth Wave Innovations Inc., [click here](#)

*Disclaimer: Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.*

---

**Dr. Rahul Kushwah on  
Predictmedix's remote patient  
monitoring technology and**

# Mobile Wellbeing

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF), about their infectious disease screening technology and remote patient monitoring platform, Mobile Wellbeing.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Kushwah talked about the successful North American deployment of Predictmedix's infectious disease screening technology at Flow Water in Aurora, Ontario. Dr. Kushwah went on to provide an update on their Mobile Wellbeing platform. "It is in telehealth and telemedicine business, but it does more than that." He continued, "It does something which is referred to as remote patient monitoring." Dr. Kushwah added that Predictmedix is targeting clinical trials and long-term care markets with its Mobile Wellbeing platform. FDA now has very strong guidance which is promoting remote patient monitoring and that brings Predictmedix's technology to the forefront.

In the interview Dr. Kushwah also said that Accenture, a multinational professional services company and a Fortune Global 500 company, recently wrote about how Predictmedix is innovating to help with the current COVID-19 pandemic (click here to read the article). "It should indicate to shareholders that not only our technology is disruptive but we are clearly in a market segment which is not only ballooning right now but is going to be huge as time goes by." Dr. Kushwah commented. To watch the full interview, click here

## **About Predictmedix**

Predictmedix develops AI technologies focused on areas which include screening for impairment, infectious disease and

mental health, and a remote patient monitoring/telehealth platform, all of which play a vital role in health and safety. Their technologies are timely to assist with the current pandemic, as well as having lasting utility that goes beyond the current crisis, extending into workplace health, safety and compliance.

To learn more about Predictmedix Inc., [click here](#)

***Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.***